Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

作者信息

Peyvandi Flora, Callewaert Filip

出版信息

N Engl J Med. 2016 Jun 23;374(25):2497-8. doi: 10.1056/NEJMc1603180.

DOI:10.1056/NEJMc1603180

PMID:27332911

Abstract

摘要

相似文献

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

N Engl J Med. 2016 Jun 23;374(25):2497-8. doi: 10.1056/NEJMc1603180.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

N Engl J Med. 2016 Jun 23;374(25):2497. doi: 10.1056/NEJMc1603180.

Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.

Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151.

Von Willebrand Factor--A New Target for TTP Treatment?

N Engl J Med. 2016 Feb 11;374(6):583-5. doi: 10.1056/NEJMe1515876.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.

Expert Rev Hematol. 2020 Nov;13(11):1153-1164. doi: 10.1080/17474086.2020.1819230. Epub 2020 Oct 12.

Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura.

Ann Hematol. 2023 Feb;102(2):457-459. doi: 10.1007/s00277-022-05049-6. Epub 2022 Nov 28.

Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.

Drugs Today (Barc). 2019 Jun;55(6):367-376. doi: 10.1358/dot.2019.55.6.2989843.

引用本文的文献

Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura.

Ann Hematol. 2024 Jul;103(7):2523-2531. doi: 10.1007/s00277-024-05771-3. Epub 2024 Apr 27.

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.

Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241241525. doi: 10.1177/10760296241241525.

ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.

Thromb Haemost. 2024 Aug;124(8):725-738. doi: 10.1055/a-2253-9359. Epub 2024 Jan 25.

Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies.

Sci Rep. 2023 Sep 5;13(1):14632. doi: 10.1038/s41598-023-41092-7.

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

Ann Blood. 2023 Jun 30;8. doi: 10.21037/aob-21-87. Epub 2022 Apr 1.

Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?

J Clin Med. 2023 Apr 25;12(9):3111. doi: 10.3390/jcm12093111.

The perfect storm: Thrombotic thrombocytopenic purpura (TTP) associated with COVID-19, a clinical case series and review.

EJHaem. 2022 Oct 26;3(4):1358-1364. doi: 10.1002/jha2.577. eCollection 2022 Nov.

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.

PLoS One. 2021 Aug 12;16(8):e0256024. doi: 10.1371/journal.pone.0256024. eCollection 2021.

Rapid Delivery of Nanobodies/VHs into Living Cells via Expressing -Transcribed mRNA.

Mol Ther Methods Clin Dev. 2020 Jan 30;17:401-408. doi: 10.1016/j.omtm.2020.01.008. eCollection 2020 Jun 12.

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.

Ther Adv Hematol. 2020 Feb 7;11:2040620720902904. doi: 10.1177/2040620720902904. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr超能文献

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr
超能文献